Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

By B. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T. Hutson, M. Michaelson, V. Gorbunova, M. Gore, I. Rusakov and 11 more. The Lancet, 2011

1,754 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2a584c30b2d19c4257d4ffd7c1788672bfe49e39

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “81) 3 [126]”
Treatment of renal cell carcinoma: Current status and future directions (2017, background): “compared with sorafenib as second-line treatment in 723 patients with metastatic ccRCC.(118) More than one-half of patients (54%) had received sunitinib, and one-third had received cytokines, before enrollment.”
Renal cell carcinoma (2017, background): “ Both axitinib and everolimus are active [48, 49].”
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, positive): “After first-line treatment with VEGF-targeted therapy:  Both axitinib and everolimus are active [48, 49].”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “In addition, axitinib, which has been reported to be more selective for VEGFRs than sunitinib 122 , significantly improved PFS compared with sorafenib in second-line treatment of metastatic renal cell cancinoma 123 .”
Cabozantinib versus everolimus in advanced renal cell carcinoma (2015, neutral): “Proteinuria 41 (12) 8 (2) 30 (9) 1 (<1)”
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Axitinib, a more recently developed TKI, has shown efficacy in the second-line setting in patients that progressed on first-line TKI therapy [16] and is now recommended for mRCC in this setting.”
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “ Both axitinib and everolimus are active [48, 49].”